Press Releases

Press Releases

Exelixis Announces Takeda And Ono Submit Supplemental Application For CABOMETYX® (cabozantinib) In Combination With OPDIVO® (nivolumab) For The Treatment Of Unresectable, Advanced Or Metastatic Renal Cell Carcinoma In Japan

Exelixis, Inc. EXEL today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX ® (cabozantinib) in Japan, and Ono Pharmaceutical Co., Ltd. (Ono), have submitted a supplemental application to the …

1 2 3 4,144